glycine has been researched along with Lymphoproliferative Disorders in 1 studies
Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 9.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| "Ixazomib is a new, orally administered, reversible proteasome inhibitor which is under investigation for the treatment of refractory/relapsed multiple myeloma (MM), systemic light chain amyloidosis (AL) and Waldenström macroglobulinemia (WM)." | 5.01 | Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. ( Rydygier, D; Smolewski, P, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smolewski, P | 1 |
| Rydygier, D | 1 |
1 review available for glycine and Lymphoproliferative Disorders
| Article | Year |
|---|---|
Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Boron Compounds; Dexamethasone; Drugs, Investi | 2019 |